Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Israeli grower receives EU-GMP certification from the German Federal Ministry of Health

Cannbit-Tikun Olam Israel's production facility in the north of Israel and cultivation farm at the Dead Sea have received the EU-GMP certification, which is required for the commercial export of medical cannabis to Europe.

This certification will make it possible to implement the agreements with the German pharmaceutical company, Fette Pharma, according to which Cannbit-Tikun Olam Israel will export its products to Germany, Austria, and Switzerland.

EU-GMP certification is required for the production, export, and marketing of pharmaceuticals throughout Europe. The certificate also applies to medical cannabis products that are defined in the European Union as pharmaceutical products available by medical prescription. The new certification will allow the company to implement the production and marketing agreements it signed to produce medical cannabis products and develop innovative administration methods that can be implemented for the various medical uses of cannabis.

As part of this effort, the company will act to sign additional global production agreements, through which the company's line of products based on clinical research will be marketed in commercial quantities worldwide.

The company is joining the highly select group of international medical cannabis companies with EU-GMP certification, which enables export and market according to the emerging global regulation.

Avinoam Sapir, CEO of Cannbit-Tikun Olam, said, "Receiving the prestigious European certification is the company's most important strategic move to date and is a true breakthrough for our company and the entire Israeli cannabis industry. Now having the certificate, we can provide an alternative for some chemical drugs, which is a clinically proven solution to improve patients' quality of life worldwide."

"From now on, our clinical research-based indication-specific products and, in the future unique and innovative administration forms will be sold in European pharmacies, and I invite pharmaceutical companies to join us to plant the seeds of the future."

For more information:

Publication date: